Target intelligence / Profile preview

Pannexin-3 (PANX3)

Target
PANX3
Molecular classification
Gap junction protein (pannexin family), Large-pore ion channel, ATP-permeable hemichannel
01

Overview

**Pannexin-3 (PANX3)** is a member of the pannexin family of large-pore, ATP-permeable channels that structurally resemble innexins (invertebrate gap junction proteins) but are distinct from connexins. PANX3 is predominantly expressed in hard tissues such as cartilage, bone, and skin, where it acts as an essential regulator of cellular differentiation and tissue development, particularly in osteoblasts, chondrocytes, and odontoblasts[1][2][4][7][8][9]. PANX3 channels function as ER Ca^{2+} channels, hemichannels for ATP release, and intercellular gap junctions, thereby controlling intracellular Ca^{2+} signaling, extracellular ATP-mediated signaling, and coordination of cell fate transitions. Genetic deletion leads to significant skeletal formation defects, indicating its indispensability for healthy bone and cartilage development. Targeted modulation of PANX3 is a topic of ongoing investigation in skeletal and regenerative medicine, but it has no clinically approved therapeutics or inhibitors at present[1][2][7][9].

Other names
Pannexin-3PANX3Px3PX3gap junction protein pannexin 3pannexin 3
02

Mechanism of action

Not applicable for any approved or clinical drugs (no specific modulators or inhibitors are currently documented for therapeutic use).

03

Biological functions

Cell–cell communicationRegulation of Ca^{2+} signalingATP release and signalingModulation of osteoblast and chondrocyte differentiationInhibition of cell proliferation (certain contexts)Promotion of odontoblast differentiation
04

Disease associations

Skeletal disorders (abnormal bone and cartilage development, osteoarthritis)Other (potential links to other tissue development and pathologies are under investigation)
05

Safety considerations

Not well established; preclinical models suggest that loss of function causes skeletal abnormalities but specific therapeutic safety challenges have not been described[2][4][7].
06

Biomarkers

No clinically validated biomarkers are established, but PANX3 expression is being investigated as a biomarker of osteogenic and chondrogenic differentiation in bone and cartilage tissue[2][7].

Beyond the preview

Go deeper on Pannexin-3 (PANX3).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pannexin-3 (PANX3).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call